Anixa Biosciences receives clearance to initiate clinical trial of breast cancer vaccine developed by Cleveland Clinic research

Anixa-Biosciences

The U.S. Food and Drug Administration has cleared an Investigational New Drug application from Anixa Biosciences Inc. (Nasdaq: ANIX) for its breast cancer vaccine, which was invented by a Cleveland Clinic research term.

This breast cancer vaccine technology was invented and developed by Cleveland Clinic immunologist Dr. Vincent Tuohy, and his research team developed the technology. Dr. Thomas Budd, a Clinic oncologist, will lead the clinical trial, according to a news release.

Click here to read the complete story.

Story excerpt provided by Crain’s Cleveland Business.

Written by Lydia Coutré.

Originally published December 21, 2020.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: